Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2019-06-21 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2019-06-20 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2019-06-20 | IntroReferral | Introduced in House | Library of Congress |